Stone X Group Inc. Iovance Biotherapeutics, Inc. Transaction History
Stone X Group Inc.
- $2.29 Trillion
- Q3 2025
Shares
1 transactions
Others Institutions Holding IOVA
# of Institutions
290Shares Held
219MCall Options Held
2.41MPut Options Held
1.7M-
Mhr Fund Management LLC New York, NY29MShares$71.5 Million10.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.1MShares$59.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$52.4 Million0.0% of portfolio
-
State Street Corp Boston, MA13.3MShares$32.9 Million0.0% of portfolio
-
Invenomic Capital Management LP Boston, MA10.5MShares$26 Million1.15% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $390M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...